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ABSTRACT 
 
OBJECTIVES: Osteoarthritis (OA) is a highly prevalent condition seen across primary care services. 
Whilst evidence-based guidelines have encouraged the prescription of medications including 
analgesics for this population, there remains uncertainty as to which types of individuals actually take 
prescribed or over-the-counter medications. The purpose of this study was to determine whether 
there is a difference in characteristics between people who are taking medicines for OA compared to 
those who are not. 
 
METHODS: A cross-sectional analysis of the English Longitudinal Study of Ageing (ELSA) cohort was 
undertaken. Individuals who reported hip and/or knee OA pain were included. Data on medication-
taking was self-reported and collected as part of the ELSA data collection programme. Logistic 
regression analyses were undertaken to determine the relationship between potential predictors 
(demographic, pathology specific, psychological, social and functional) and whether individuals took 
medications for their OA symptoms. 
 
RESULTS: 654 participants reported OA; 543 medicine-takers and 111 non-takers. Individuals who 
had access to a car (Odd Ratio (OR): 56.2; 95% Confidence Intervals (CI): 3.35 to 941.36), those with 
a greater duration of hip pain (OR: 5.79; 95% CI: 1.40 to 24.0) and those who achieved 10 chair raises 
at speed (OR: 1.08; 95% CI: 1.03 to 1.14) are more likely to take OA medicines.  
 
CONCLUSIONS: This study identified predictors to medication-taking in individuals with hip and/or 
knee OA. Strategies are now warranted to better support these individuals, to improve health and 
wellbeing for this long-term, disabling condition. 
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INTRODUCTION 
 
Osteoarthritis (OA) is a disabling chronic musculoskeletal condition associated with high disability-
adjusted life years and low quality of life for those with poor symptom control (GBD 2015 DALYs and 
HALE Collaborators, 2015). It is a highly prevalent condition seen across primary care services, 
constituting an increasing proportion of the case loads of general practitioners, physiotherapists, 
community pharmacists and other health professionals (Lancey et al, 2014; Ferreira de Meneses, 
2016). Current evidence-based management advocated across international guidelines include weight-
management, education, exercise and medication in the form of analgesics and non-steroidal anti-
inflammatory drugs (NSAIDS) (National Clinical Guideline Centre, 2017; Zhang et al, 2007). Whilst 
these have demonstrated moderate to good effect sizes for those who follow this advice, patient 
experiences surrounding the effectiveness, particularly of paracetamol, have been shown to influence 
the extent to which pain relief is used (Lee et al, 2017). Furthermore, Wang et al (2005) highlighted the 
importance which some medications, such as strontium ranelate, may offer in respect to symptom 
improvement and joint structure changes with a slowing of disease progression (Rodrigues et al, 2018). 
Accordingly, encouraging the management of OA symptoms with medicines, particularly in the early 
stages of the disease, could have longer-term beneficial consequences (Han et al, 2017). 
 
Previous research has suggested that increasing age, gender, social circumstance, education and 
socioeconomic status may be associated with medication-taking for people with musculoskeletal pain 
(Mody et al, 2008; Pokela et al, 2010; Fisher et al, 2012). Pain severity and mobility limitation have also 
been identified as important factors for those with chronic pain (Mody et al, 2008; Pokela et al, 2010; 
Fisher et al, 2012). However, due to limited sample sizes and variation in how musculoskeletal pain is 
categorised, there remains confusion as to who is most likely to take medication for this condition. It 
also remains unclear whether medication-taking for OA medications differs to that of other chronic 
diseases which this population may also have and to what extent taking medicines for other conditions 
influences taking medicines for OA. As such, it is important to ascertain if those already taking 
medicines for these conditions are more likely to take medicines for OA as this could significantly impact 
on both their health and well-being (Fisher et al, 2012).  
 
Based on these uncertainties, the purpose of this analysis was to determine whether there is a 
difference in characteristics between people who are taking medicines for OA compared to those who 
are not. We also compared medication-taking for OA to other long-term conditions such as diabetes, 
hypertension or thrombotic diseases. 
 
METHODS 
 
Cohort 
 
Data were gathered from the English Longitudinal Study of Ageing (ELSA), a prospective, population-
based cohort study consisting of 11,391 individuals born on or before 29th February 1952 (Steptoe et 
al, 2013). It is a nationally-representative cohort which commenced in 2002 and has been followed 
every two years since (Steptoe et al, 2013). Ethical approval was provided by the London Multi-Centre 
Research Ethics Service (MREC/01/2/91). Anonymised unlinked data for this study were obtained from 
the UK Data Service. 
 
Participants 
 
Participants were eligible if they reported hip and/or knee OA with a visual analogue scale (VAS) pain 
score of one or above from a 0 to 10 pain scale. A threshold of VAS pain score of one was adopted to 
ensure that included participants presented with symptomatic arthritis. Whilst it is acknowledged that 
this may be considered low, the mean and standard deviation (SD) values indicate that the cohort had 
substantially greater pain scores than the one-point threshold (hip: 6.9; SD: 1.9/knee: 5.0; SD: 2.9). 
Included respondents were also required to report whether they were or were not taking medications 
for OA symptoms.  
 
Data Collection 
 
Data were gathered from Wave 4 of the ELSA cohort (2008-2009). The sample was drawn from 
participants in the Health Survey for England (HSE) 1998, 1999 and 2001 survey with Wave 4 including 
a refreshment sample from HSE 2006 (Steptoe et al, 2013). The HSE is an annual cross-sectional 
survey that is designed to monitor the health of the general population. The total sample of 11,050 from 
Wave 4 included 8643 who attended a nurse visit to collect biomarkers and more detailed measures of 
function. Data from this analysis consisted of participants who attended the nurse clinic with wider 
demographic information gathered from the face-to-face follow-up interviews. 
 
For this analysis, all potentially eligible participants presenting data for analysis, were included. This 
consisted of a cohort of 654 participants.  
 
Dependent Variables 
 
Medication-taking was self-reported and categorised in a binary code of yes/no. Medication-taking was 
asked towards OA medication, in addition to anticoagulation, diabetes and hypertension medications 
which were collected as part of the routine data collection processes for the wider ELSA study.  
 
Covariates 
 
Data on covariates were identified from the ELSA Wave 4 data as having a plausible relationship to 
explain medication taking for this population from a biological, psychological or social stand-point. 
Accordingly the data included in the analysis were: participant age, gender, weight, ethnic classification 
(white/non-white), whether participants were in paid work or not and the National Statistics-Socio-
Economic Classification scheme (NS-SEC) category (Shankar et al, 2011). We also extracted data on 
self-reported general health and whether participants had access to a car. It was therefore hypothesised 
that these data may provide some explanation to medication-taking from perspectives such as disease-
specific, impairment or activity related, from social or economic factors in addition to representing health 
psychological factors across this national cohort (Steptoe et al, 2013). 
 
Pain measurements extracted included: VAS hip and knee pain score, duration of hip and/or knee pain 
and location of OA categorised as either isolated hip, isolated knee or hip and knee. 
 
Physical activity participation was determined through the self-reported ELSA physical activity 
questionnaire (ELSA-PAQ)(Hamer et al, 2009). Participants were asked how often they engaged in 
vigorous, moderate or mild physical activity (Garfield et al, 2016; Demakakos et al, 2010). This method 
has been used to determine the level of physical activity participation undertaken by older people 
(Garfield et al, 2016; Demakakos et al, 2010), and has demonstrated excellent convergent validity within 
this population (Hamer et al, 2009).  
 
Cognitive function was determined using the ELSA index of executive function. This is based on two 
brief tests of executive function: verbal fluency and letter cancellation. 
 
Verbal fluency: this evaluates self-initiated activity, organisation and abstraction/mental flexibility. For 
this task, participants were given one minute to name as many animals as possible. The number of 
animals named was recorded)  
Letter cancelation: this assesses attention, visual searching and mental speed. Participants were 
provided with a page of random letters arranged in rows and columns and asked to cross out as many 
target letters (‘P’ and ‘W’) within one minute (Steptoe et al, 2013).  
 
These have demonstrated reliability and validity in assessing executive function (Henry & Crawford, 
2004; Lezak, 1995; Tombaugh et al, 1999; Uttl and Pilkenton-Taylor, 2001).  
 
Objectively assessed physical performance measurements were collected during the nurse 
assessment visit. These included: gait speed using an eight feet (2.4 m) walking test performed at 
normal walking pace, dominant handgrip strength, and timed chair raises (five and 10 repetitions) 
completed.  
 
Functional impairment in activities of daily living (ADL) and instrumental ADLs was assessed by 
participant’s response to whether they found difficulty in performing 18 personal and extended activities 
of daily living (Steptoe et al, 2013). These are itemised in Table 1. 
 
Data Analysis 
 Demographic characteristics were presented using mean, standard deviation and frequency values. 
The frequency and prevalence with 95% confidence intervals (CI) of responses for taking OA 
medications, anticoagulation, diabetes and hypertension medication was determined.  
 
Data distribution was assessed using the Shapiro-Wilks test. This indicated normality for each analysis 
undertaken. The primary analysis was an assessment for a potential association between candidate 
covariates comparing taking and not taking OA medications was determined using a Chi-squared test 
(for categorical variable) and Student T-Test (for continuous variables). Using these results, candidate 
variables which demonstrated a significance at P≤0.10 were included in a binary logistic regression 
analysis. This was used to determine the association between characteristics for participants who took 
and did not take medications for hip and/or knee OA. Data were presented as odd ratio (OR), 95% 
confidence intervals (CI) and p-values. For the final logistic regression model, p<0.05 denoted statistical 
significance. Finally, a secondary analysis through a Chi-squared test was undertaken to determine 
whether there was a difference in medication-taking for OA compared to medication-taking for diabetes, 
hypertension or thrombotic complications. All analyses were performed in Stata version 14.0 (StatCorp, 
Texas, USA).  
 
RESULTS 
 
Cohort 
 
Of the 11,050 participants included in the Wave 4 ELSA dataset, data were missing on OA medication-
taking for 10,396 participants. From the remaining 654 participants, all of whom had OA, 543 (83.0%; 
95% CI: 0.80 to 0.86) reported taking medicines for OA, whilst 111 (17.0%; 95% CI: 0.14 to 20.0) 
reported not taking medicines.  
 
Characteristics of Cohort 
 
Table 1 summarises the cohort characteristics for those who were taking or not taking medicines for 
hip and/or knee OA. As this illustrates, there was a difference between the groups in respect to 
demographic characteristics. Those who took OA medicines more frequently had access to a car 
(87.3% versus 28.0%; p<0.001), higher mean fluency executive function (5.33 points versus 2.69 
points; p<0.001), were younger (66.5 years versus 68.7 years; p=0.04), reported poorer self-reported 
health (fair to poor: 72.5% versus 54.9%; p=0.093) and were of a higher socioeconomic group 
(managerial or intermediate occupations: 32.2% versus 27.9%; p=0.142), although some of these 
differences were not significant.  
 
There was a difference in the location of OA with those who were taking medicines presenting with a 
greater proportion of multi-joint OA (hip and knee: 47.3% versus 33.3%; p=0.003), with higher hip VAS 
pain scores (6.97 versus 6.37; p=0.009) and lower knee VAS pain scores (4.82 versus 5.59; p=0.013). 
Those who took medicines also reported a greater duration of hip pain (≥12 months: 54.3 versus 45.0; 
p=0.037).  
 
Those who took medicines for OA were more likely to perceive OA medication as effective (24.3% 
versus 35.9%; p<0.001). Those who took medicines presented with shorter time to complete 10 chair 
raises (24.9 second versus 28.2 second; p=0.015). There was no difference between the groups for 
self-reported activity of daily living impairment, duration of knee pain, physical activity participation, 
whether they were in paid work or not, ethnicity, gender or weight (Table 1).  
 
Logistic Regression Analysis 
 
Age, access to a car, NS-SEC socioeconomic group category, self-reported health, executive function, 
location of OA, pain score, duration of hip pain dominant handgrip strength, timed 10 chair raises and 
perception of OA medication were identified as candidate variables for the binary logistic regression 
model, reaching the p≤0.10 threshold. The results of the logistic regression analysis are presented in 
Table 2. When analysed, access to a car, the duration of hip pain and timed 10 chair raises were 
significant variables. Those who had access to a car were 56 times more likely to take OA medicines 
compared to those who did not have access to a car (OR: 56.2; 95% CI: 3.350 to 941.36). Those with 
a greater duration of hip pain were nearly six times more likely to take OA medications compared to 
those who had a shorter duration than 12 months (OR: 5.79; 95% CI: 1.40 to 24.0). People who 
achieved 10 chair raises faster were 8% more likely to take medications for OA symptoms (OR: 1.08; 
95% CI: 1.03 to 1.14). There was no significant difference between OA medication-taking for variables 
such as age, NS-SEC socioeconomic group category, self-reported health, executive function, location 
of OA, dominant grip strength and perception of OA medication (Table 2). 
 
There was no significant relationship between OA medication-taking compared to medication-taking for 
other chronic diseases is presented in Table 3. As this illustrates, there was no relationship between 
OA medication-taking and those for anticoagulants (p=0.78), medicines for diabetes (p=0.79) or 
medicines for hypertension (p=0.65).  
 
CONCLUSIONS 
 
The findings of this study indicate that three variables were associated with whether individuals took 
medication for their OA symptoms. Individuals who had access to a car, had a longer duration of hip 
pain and those who could complete 10 raises from a chair faster were more likely to take medications 
for their OA. There was no relationship between taking medications for OA compared to anticoagulants 
or medicines for diabetes or hypertension. Given that taking medicines may slow OA disease 
progression (such as though strontium ranelate (Rodrigues et al, 2018)) and improve both pain and 
structural changes (Wang et al, 2015; Han et al, 2017), encouraging medicine-taking for these people 
at most risk of not is clinically warranted. This is further encouraged by this data where there was a 
signal for greater functional performance, as measured by timed chair raises, for individuals who took 
medications compared to those who did not. This suggests that individuals who take medications may 
be more physically capable compared to those who do not.  
 
The duration of hip pain was reported as a significant predictor in medication-taking. This may relate to 
people having a greater time period and therefore opportunity to take medicines (Rillo et al, 2016). It 
was not possible to negate the problem of reverse causation using concurrent measures of pain and 
medication-taking. Nonetheless, duration of hip pain may also relate to long-term health beliefs, 
advocating the advantages of medication control for hip symptoms. Whilst reported as a potential 
candidate variable, the variables of hip and knee pain scores were not reported as significant predictors. 
This contrasts to previous findings which suggests that pain severity and associated reduced mobility 
are significant predictors in other musculoskeletal cohorts (Mody et al, 2008; Pokela et al, 2010; Fisher 
et al, 2012). The mean VAS scores for the cohorts were between five to seven. Therefore, it remains 
unclear whether medication-taking is different between participants with higher or lower scores, given 
that the cohort presented with minimal variance. Further exploration with cohorts who present with 
different pain severities may therefore be prudent.  
 
There was a difference in medication-taking between people who reported hip, knee or multi-site OA. 
A greater proportion of participants with hip and knee OA presented in the medication-taking group 
(47%). It is unclear why this should be the case. One hypothesis is a difference in health beliefs towards 
managing more global (all-body) symptoms with medications of those with multi-site OA compared to 
individuals with single-joint pathology. There remains limited evidence around different symptom 
management approaches for those with single-joint compared to multi-joint pathology (Comer et al, 
2018). Further exploration on why individuals with multi-joint pain are more likely to take medications 
would be useful. Examination of previous consultations with health care professionals, symptoms levels 
and attitudes towards OA would all be beneficial areas for investigating to better understand why this 
difference occurs.   
 
The findings of this study indicate no association between medication-taking with OA to other chronic 
diseases. This conflicts with previous literature which has suggested a disconnect in practices where 
people are more likely to take medications for cardiovascular disease and diabetes management 
compared to OA (Sale et al, 2006). These studies have suggested that patients were more likely to take 
medications to control blood pressure, blood sugar or reduce the risk of thrombotic events. The 
difference may be attributed to either a difference in outcome for this population compared to those who 
are older and from other countries to France (Alami et al, 2011), Australia (Laba et al, 2013; Milder et 
al, 2011) and Canada (Sale et al, 2006) where the current evidence arises from. The results may also 
be attributed to this sample size where the subgroup analysis consisted of between 90 to 259 
participants (Table 3) and therefore the non-statistically significant finding may be attributed to type two 
statistical error.  
 
Previous research has suggested that increasing age, gender, social circumstance, education, and 
socioeconomic status in addition to pain severity and mobility impairment may be associated with 
medication use (Mody et al, 2008; Pokela et al, 2010; Fisher et al, 2012). This cohort of community-
dwelling individuals from England suggests that whilst there was no significant relationship on logistical 
regression analysis on medication adherence for age, gender or education, the variable as to whether 
individuals have access to a car may be viewed as a surrogate for social circumstance or 
socioeconomic status. It remains unclear whether this factor should be interpreted in respect to the 
economics of not being able to afford access to transport, which has been previously reported as a 
factor (Macintyre et al, 1998), or whether this should be interpreted as a marker for social isolation and 
loss of social capital (Drennan et al, 2008). Both factors have been suggested to have major impact on 
quality of life (Woodcock and Aldred, 2008) and hence should be considered as important factors for 
people with osteoarthritis. 
 
This study has highlighted subgroups of the OA population who are at risk of not taking medications 
(i.e. people without access to a car, those with a shorter duration of disease and who take longer to 
complete 10 chair raises). Previous literature has identified strategies, which health professionals may 
adopt to address such behaviours. These include educating patients about conditions and medicines, 
so they understand their value, identifying barriers and facilitators to medication-taking and action 
planning and monitoring to support individuals (Roberts et al, 2014; Gellad et al, 2011). Accordingly, 
these people who have been identified at greatest risk of not taking medications should be better 
supported through education on the different types of medicines available and how to use them to 
relieve symptoms and improve their health and wellbeing.  
 
Whilst this study has considerable strengths, most notably its size for the primary analysis and national-
representation for people who present with OA, it presented with two key limitations. Firstly, the findings 
on medication-taking were self-reported. Accordingly, both recall and social desirability bias may have 
affected findings to either supress or inflate estimated medication-taking practice. This may have been 
negated through validation techniques of medication-taking such as pill count or reported prescription 
counts. However, since the data from the ELSA cohort is anonymised, such validation approaches 
could not be undertaken. Secondly, it was not possible to ascertain whether there was a difference in 
medication-taking between simple medications such as paracetamol, non-steroid anti-inflammatories 
compared opioid-based medications. Assessing differentiation of medication-taking by medication type 
would provide further granularity to the analysis and may provide greater insights into medication-taking 
behaviours of people with OA.  
 
To conclude, the findings of this study indicate that access to a car, duration of hip pain and time to 
complete 10 chair raises are significant predictors as to whether individuals with hip and/or knee OA 
take medications. Further study to consider what strategies should be used to better support these 
individuals at greater risk would be advantageous given the current evidence-based recommendations 
that medication-taking can significantly improve the health and wellbeing of these individuals and 
reduce the burden of not taking medicines for OA symptoms on primary and secondary care services.  
 
  
TABLE AND FIGURE LEGENDS 
 
Table 1: Demographic characteristics of individuals who reported taking compared to not taking 
medications for hip and knee osteoarthritis. 
  
Table 2: Results of the logistic regression analysis to determine the probability of people taking and 
not taking medications for hip and knee osteoarthritis. 
  
Table 3: Results of the analysis comparing medication-taking to osteoarthritis medication to 
medications for three other chronic diseases. 
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Table 1: Demographic characteristics of individuals who reported taking compared to not taking 
medications for hip and knee osteoarthritis. 
 
 Hip or Knee P-Value 
Taking OA 
Medications 
Not Taking OA 
Medications 
N 543 111  
Mean Age (SD) 66.45 (10.04) 68.65 (9.76) 0.035 
Mean weight in Kg (SD) 162.71 (10.02) 162.44 (9.68) 0.819 
Gender  
Male 171 (31.5) 34 (30.6) 0.911 
Female 372 (68.5) 77 (69.4) 
Access to a car (yes;%) 411 (87.3) 26 (28.0) <0.001 
Ethnicity 
White 517 (95.2) 109 (98.2) 0.291 
Non-white 25 (4.6) 2 (1.8) 
In paid work (yes) 128 (27.2) 26 (28.0) 0.877 
NS-SEC 5 Category  
1: Managerial and professional occupations 114 (21.0) 24 (21.6) 0.142 
2: intermediate occupations 61 (11.2) 7 (6.3) 
3: Small employers and own account workers 42 (7.7) 13 (11.7) 
4: Lower supervisory and technical occupations 64 (11.8) 18 (16.2) 
5: Semi-routine and routine occupations 232 (42.7) 43 (38.7) 
Not reported 30 (5.5) 6 (5.4) 
Self-Reported Health 
Excellent 2 (0.4) 24 (21.6) 0.093 
Very Good 30 (5.5) 7 (6.3) 
Good 117 (21.5) 13 (11.7) 
Fair 207 (38.1) 18 (16.2) 
Poor 187 (34.4) 43 (38.7) 
Not reported 0 6 (5.4) 
Mean Fluency Executive Function score 5.33 (2.24) 2.69 (2.59) <0.001 
Physical Activity Participation 
Low 191 (35.2) 32 (28.8) 0.327 
Moderate 224 (41.3) 50 (45.0) 
High 58 (10.7) 17 (15.3) 
Not reported 70 (12.9) 12 (10.8) 
Location of OA 
Knee (yes; %) 230 (42.4) 52 (46.8) 0.003 
Hip (yes; %) 56 (10.3) 22 (19.8) 
Hip and Knee (yes; %) 257 (47.3) 37 (33.3) 
Pain 
Mean Hip VAS (SD)  6.97 (1.84) 6.37 (1.96) 0.009 
Mean Knee VAS (SD) 4.82 (2.96) 5.59 (2.75) 0.013 
Duration of hip pain  (N=110) 
< 3 months 1 (0.18) 0 0.037 
≥3 < 6 months 1 (0.18) 0 
≥6 months < 12 months 16 (2.94) 9 (8.1) 
≥ 12 months 295 (54.33) 50 (45.0) 
Not Reported  313 (57.64) 52 (46.8) 
Duration of knee pain  (N=387) 
< 3 months 1 (0.18) 1 (0.9) 0.400 
≥3 < 6 months 2 (0.37) 0 
≥6 months < 12 months 27 (4.97) 7 (6.3) 
≥ 12 months 457 (84.16) 81 (73.0) 
Not reported  56 (10.31) 22 (19.8) 
Functional Capability 
Mean grip strength: dominant hand in Kg (SD)  23.55 (10.92) 21.73 (10.34) 0.137 
Mean timed 5 chair raises completed (SD) 12.94 (5.11) 13.70 (4.25) 0.259 
Mean timed 10 chair raises completed (SD) 24.90 (8.24) 28.16 (8.30) 0.015 
Self-reported ADL impairment 
Walking 100 yards 69 (12.7) 12 (2.2) 0.580 
Sitting for two hours 68 (12.1) 17 (3.1) 0.425 
Getting up from a chair 143 (25.4) 23 (4.2) 0.216 
Ascending several flight of stairs 203 (36.1) 37 (6.8) 0.420 
Ascending one flight of stairs without resting 80 (14.2) 13 (2.4) 0.406 
Stooping, kneeling or crouching 207 (36.8) 41 (7.6) 0.815 
Reaching to lift something above shoulder level 68 (12.1) 12 (2.2) 0.616 
Pushing or pushing large objects 101 (17.9) 17 (3.1) 0.412 
Carrying a weight of over 10 pounds 134 (23.8) 27 (5.0) 0.937 
Picking 5 pence from a table 36 (6.4)  6 (1.1) 0.632 
Dressing including putting shoes and socks on 74 (13.1) 14 (2.6) 0.775 
Walking across a room 18 (3.2) 3 (0.6) 0.739 
Bathing or showering 54 (9.6) 14 (2.6) 0.401 
Eating including cutting up foot 10 (1.8) 1 (0.2) 0.483 
Getting in and out of bed 23 (4.1) 8 (1.5) 0.179 
Toileting including getting up or down 18 (3.2) 1 (0.2) 0.168 
Shopping for groceries 51 (9.1) 10 (1.8) 0.899 
Doing work around the house or garden 84 (14.9) 17 (3.1) 0.967 
Medication Taking Behaviour 
Perception that OA medication is effective (yes; %) 295 (54.3) 14/39 (35.9) <0.001 
Medication-taking: anticoagulants (yes; %) 95/170 (55.9) 22/36 (61.1) 0.822 
Medication-taking: diabetes medication (yes; %) 72/90 (80.0) 14/18 (77.8) 0.974 
Medication-taking: hypertensive (yes; %) 233/259 (90.0) 42/45 (93.9) 0.477 
 
ADL – activities of daily living; Kg- kilograms; N – number of participants; NS-SEC – National 
Statistics Socio-economic classification; OA – osteoarthritis; SD – standard deviation 
 
  
Table 2: Results of the logistic regression analysis to determine the probability of people taking and 
not taking medications for hip and knee osteoarthritis. 
 
Variable Odd Ratio 95% CI P-value 
Executive Function 0.595 0.339-1.044 0.232 
Age  1.050 0.886-1.244 0.572 
Dominant Grip 
Strength 
0.947 0.848-1.057 0.330 
Site of OA 2.215 0.649-7.558 0.204 
VAS Hip Score 0.108 0.010-1.148 0.065 
VAS Knee Score 1.240 0.591-2.602 0.569 
Perception OA 
medication works 
5.210 0.420-64.667 0.199 
NS-SEC Group 0.509 0.206-1.261 0.145 
Access to Car 56.155 3.350-941.364 0.005 
Duration Hip Pain  5.793 1.397-24.021 0.015 
Self-Reported Health  4.812 0.581-39.850 0.145 
Timed 10 Chair 
Raises  
1.082 1.026-1.142 0.004 
Classification – percentage correct: 92.4% 
 
B – beta-value; CI – confidence intervals; NS-SEC – National Statistics Socio-economic classification; 
OA – osteoarthritis; VAS – visual analogue scale 
 
 
 
 
  
Table 3: Results of the analysis comparing medication-taking to osteoarthritis medication to 
medications for three other chronic diseases. 
 
 Medication-taking OA 
medication (%) 
Chi2  
P-value 
Anticoagulant 95/170 (55.9) 0.779 
Diabetes 72/90 (80.0) 0.786 
Hypertension 233/259 (90.0) 0.648 
OA - osteoarthritis 
 
 
 
 
